Polymorphism in the ortholog gene of the Plasmodium falciparum K13 gene was investigated in Plasmodium vivax isolates collected in Cambodia. All of them were Sal-1 wild-type alleles except two (2/284, 0.7%), and P. vivax K12 polymorphism was reduced compared to that of the P. falciparum K13 gene. Both mutant allele isolates had the same nonsynonymous mutation at codon 552 (V552I) and were from Ratanak Kiri province. These preliminary data should encourage additional studies for associating artemisinin or chloroquine resistance and K12 polymorphism.
In areas in which malaria is endemic and Plasmodium falciparum and Plasmodium vivax are present, such as in Southeast Asia and Pacific Oceania, both species share the same vectors and human hosts, either successively or concomitantly (mixed infections) (1, 2). These two species, in this context, often undergo similar mutation-driven evolution and natural selection. This includes nucleotide substitution, gene duplication/deletion, chromosomal change, and genome duplication (3). In terms of drug resistance, regardless of the fundamental biological differences between the two Plasmodium species, it is well known that antimalarial drug pressure induces a strong selection of resistant parasites for both of these parasite populations. For instance, sequencing of the dhfr gene in P. vivax isolates collected in areas where sulfadoxine-pyrimethamine was used to treat falciparum malaria and the alignment of these alleles with the P. falciparum dhfr gene have clearly demonstrated that mutations in codons 57, 58, 61, 117, and 173 were involved in pyrimethamine resistance and corresponded to the codons 51, 59, 108, and 164 found in P. falciparum pyrimethamine-resistant strains (4). More recently, we observed high frequencies of P. falciparum and P. vivax isolates with increased mdr-1 copy numbers in areas where mefloquine has been extensively used as the first-line treatment in falciparum-uncomplicated malaria, while in areas where mefloquine has never been used, P. falciparum and P. vivax isolates with increased mdr-1 copy numbers are rare (5). These studies clearly show that antimalarial drugs used to treat falciparum malaria have a significant impact on sympatric Plasmodium species, such as P. vivax.Since 2001, artemisinin combination therapies (ACTs) have been recommended as first-line treatment in the national treatment guidelines of most countries in which malaria is endemic. In 2008, the emergence of artemisinin-resistant P. falciparum parasites was observed in Southeast Asia (6-15). Recent molecular and biological studies showed that artemisinin resistance was associated with P. falciparum early ring stages and mutations in the PF3D7_1343700 kelch propeller domain (K13-propeller) (8,14,15). To date, although the role of the P. falciparum K13 protein remains unknown, two pieces of evidence suggest that it is involved in the cellular response to oxidative stress (8): (i) its homology to the KEAP1 human protein, which is involved in cell adaptation to oxidative stress (16), a...